News articles for Transcept Pharmaceuticals, Inc.:
Tuesday, February 7, 2012
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences
POINT RICHMOND, Calif., Feb. 7, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at two ...
read more Wednesday, December 21, 2011
Thursday, December 8, 2011
Wednesday, November 30, 2011
Transcept Pharmaceuticals to Host Conference Call to Discuss Purdue's Exercise of Option to Commercialize Intermezzo® in the United States
POINT RICHMOND, Calif., Nov. 30, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it will host a conference call to discuss the exercise by Purdue of its option to commercialize Intermezzo® (zolpidem tartrate) sublingual tablet C-IV in the United States.
Conference Call InformationDate: ...
read moreWednesday, November 23, 2011
Transcept Pharmaceuticals Announces FDA Approval of Intermezzo® (zolpidem tartrate sublingual tablet) C-IV For Use as Needed for the Treatment of Insomnia When a Middle-of-the-Night Awakening is Follo
Point Richmond, Calif., Nov. 23, 2011 /PRNewswire/ --Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that the U.S. Food and Drug Administration (FDA) has approved Intermezzo® (zolpidem tartrate sublingual tablet)( )C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by ...
read moreThursday, November 10, 2011
Transcept Pharmaceuticals Reports Third Quarter 2011 Financial Results
POINT RICHMOND, Calif., Nov. 10, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and nine months ended September 30, 2011.
(Logo: ...
read more Wednesday, November 2, 2011
Monday, October 24, 2011
Transcept Pharmaceuticals to Present at the BIO Investor Forum on October 26, 2011
POINT RICHMOND, Calif., Oct. 24, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at the BIO Investor Forum ...
read more Thursday, October 13, 2011
Tuesday, October 4, 2011
Tuesday, September 27, 2011
Transcept Pharmaceuticals Resubmits Intermezzo® NDA to FDA
POINT RICHMOND, Calif., Sept. 27, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo® (zolpidem ...
read more Tuesday, September 20, 2011
Wednesday, September 14, 2011
Tuesday, September 13, 2011